본문 바로가기
KERD
논문KCI 등재

High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma: an Eight-Year Experience

정준원|한지숙|장현
연세대학교의과대학 (Yonsei University College of Medicine)|2006.10|Yonsei Medical Journal|제47권 제5호|pp. 604-613

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류의학일반

초록

Autologous stem cell transplantation (ASCT) is commonly used in relapsed or refractory non-Hodgkin's lymphoma (NHL). Several trials report the role of ASCT for high risk patients. We evaluated the results and the prognostic factors influencing the therapeutic effects on the patients who were treated with high dose chemotherapy (HDC) and autologous peripheral stem cell transplantation. We analyzed the data of 40 cases with NHL who underwent ASCT after HDC. Twenty- four patients had high-risk disease, 12 cases sensitive relapse, and two cases resistant relapse or primary refractory each. The median age of patients was 34 years (range, 14-58 years). The median follow-up duration from transplantation was 16 months (range, 0.6-94 months). Estimated overall survival and progression-free survival at 5 years were 40% and 30%, respectively. Poor prognostic factors for survival included older age (≥45 years), poor performance status in all patient analysis, and a longer interval between first complete remission and transplantation in high risk patients. In high risk NHL patients, transplantation should be done early after first complete remission to overcome chemo-resistance.

Abstract

Autologous stem cell transplantation (ASCT) is commonly used in relapsed or refractory non-Hodgkin's lymphoma (NHL). Several trials report the role of ASCT for high risk patients. We evaluated the results and the prognostic factors influencing the therapeutic effects on the patients who were treated with high dose chemotherapy (HDC) and autologous peripheral stem cell transplantation. We analyzed the data of 40 cases with NHL who underwent ASCT after HDC. Twenty- four patients had high-risk disease, 12 cases sensitive relapse, and two cases resistant relapse or primary refractory each. The median age of patients was 34 years (range, 14-58 years). The median follow-up duration from transplantation was 16 months (range, 0.6-94 months). Estimated overall survival and progression-free survival at 5 years were 40% and 30%, respectively. Poor prognostic factors for survival included older age (≥45 years), poor performance status in all patient analysis, and a longer interval between first complete remission and transplantation in high risk patients. In high risk NHL patients, transplantation should be done early after first complete remission to overcome chemo-resistance.

참고문헌 (42)

  1. "Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide", pp.1705~10, vincristine and prednisone
  2. "State-of-the-art therapeutics: diffuse large B-cell lymphoma", 23, pp.6387~6393 (2005)
  3. "Treatment of non-Hodgkin's lymphoma", pp.1023~30
  4. "Comparision of a standard regimen with three intensive chemotherapy regimens for advanced non-Hodgkin`s lymphoma", pp.1002~6
  5. "BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin`s lymphoma", 13, pp.588~595 (1995)
  6. "High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma", pp.1493~8
  7. "Intensive cytotoxic therapy followed by autologous bone marrow transplantation for non-Hodgkin's lymphoma of high- grade malignancy", pp.984~9
  8. "Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin's lymphoma", 333, pp.1540~1545 (1995)
  9. "Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma", 18, pp.3025~3030 (2000)
  10. "VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma", 16, pp.2796~2802 (1998)
  11. "Randomized study to evaluate the use of high-dose therapy as part of primary treatment for aggressive lymphoma", 20, pp.4413~4419 (2002)
  12. "Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma", 21, pp.1255~1262 (2003)
  13. "Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma", 20, pp.2472~2479 (2002)
  14. "Non-Hodgkin lymphoma: an update", 5, pp.341~353 (2004)
  15. "Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index", 15, pp.1419~1424 (2004)
  16. "High dose Therapy improves progression-free survival and survival in relapsed follicular non- Hodgkin`s lymphoma results from the randomized European CUP trial", 21, pp.3918~3927 (2003)
  17. "Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma", 11, pp.129~135 (2005)
  18. "National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas summary and description of a working formulation for clinical usage", the(n-hodgkin's lymphoma pathologic classification project), pp.2112~35
  19. "International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury", 17, pp.423~429 (1999)
  20. "Randomised trial of filgrastin-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients", 347, pp.353~357 (1996)
  21. "Report of an international workshop to standardize response criteria for non- Hodgkin's lymphomas", 17, pp.1244~1253 (1999)
  22. "A predictive model for aggressive non-Hodgkin's lymphoma", pp.987~94
  23. "High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group", 14, pp.140~151 (2003)
  24. "High-dose therapy followed by autologous stem cell transplantation in non-Hodgkin`s lymphoma; a single center experience", 9, pp.12~18 (2004)
  25. "High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin`s lymphoma: a single-center experience of 50 patients", 19, pp.114~120 (2004)
  26. "High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience", 31, pp.279~289 (2001)
  27. "High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience", 14, pp.1768~1775 (2003)
  28. "Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)", 92, pp.76~82 (1998)
  29. "The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities", 50, pp.696~702 (2000)
  30. "Eight-year experience of malignant lymphoma; survival and prognostic factors", 38, pp.270~284 (1997)
  31. "REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features", 83, pp.806~812 (1998)
  32. "Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting", 98, pp.983~992 (2003)
  33. "Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial", 21, pp.1255~1262 (2003)
  34. "Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support", 350, pp.1287~1295 (2004)
  35. "Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor- risk, aggressive non-hodgkin's lymphoma", 23, pp.3793~3801 (2005)
  36. "Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission", 19, pp.406~413 (2001)
  37. "Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL", TAMO experience, 2004, pp.15, 1504~1509
  38. "Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front- line autotransplantation after complete remission", 15, pp.2826~2834 (2004)
  39. "Transplantation strategies for patients with follicular lymphoma", 12, pp.266~272 (2005)
  40. "Nonmyeloablative stem cell transplantation in a patient with NK", T cell lymphoma, 2001, pp.6, 229~236
  41. "Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?", 29, pp.183~189 (2002)
  42. "High dose chemotherapy and stem cell rescue for aggressive non- Hodgkin's lymphoma", 39, pp.617~625 (1997)

관련 논문AI추천

Prognostic Factors in Non-Hodgkin’s Lymphoma Patients Treated by Autologous Stem Cell Transplantation: A Single Center ExperienceCheolwon Suh, Eun Kyung Kim, Geundoo Jang, Hee Jung Sohn, Hyo Jung Kim, Jooryung Huh, Jung Shin Lee, Ok Bae Ko, Sang Hee Kim, Shin Kim, Wookun Kim대한암학회 · Cancer Research and Treatment2005 · 제37권 제5호Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients이석, 김유진, 김종욱, 김희제, 민우성, 민창기, 박장원, 엄기성, 윤재호, 이성은, 이종욱, 전영우, 조석구대한내과학회 · The Korean Journal of Internal Medicine2015 · 제30권 제3호Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement고옥배, 서철원, 허주령, Geundoo Jang, Shin Kim대한내과학회 · The Korean Journal of Internal Medicine2008 · 제23권 제4호Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma강은석, 고영혜, 김석진, 김원석, 맹치훈, 임도훈, 최준영대한암학회 · Cancer Research and Treatment2017 · 제49권 제1호Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)박용, 강혜진, 공지현, 곽재용, 김경하, 김원석, 김훈구, 도영록, 문영철, 박무림, 박성규, 신호진, 양덕환, 오성용, 원종호, 이재훈, Mark Lee대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호림프종과 골수종 환자에서 자가 조혈모세포 이식술의 현실 세계 경험김신, 박정선, 서철원, 이경민, 조형우대한내과학회 · 대한내과학회지2021 · 제96권 제6호

이 간행물의 다른 논문 (10건)

Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People강희철, 조희정, 윤방부, 이규래, 김경곤pp. 614-625The Effect of Fish Consumption on Blood Mercury Levels of Pregnant Women김인규, 김의혁, 김상운, 권자영, 박용원pp. 626-633High Prevalence of Ceftazidime-Resistant Klebsiella pneumoniae and Increase of Imipenem-Resistant용동은, 김희준, 이경원, 정윤섭, 임장현, 조지현, 어영, 이위규pp. 634-645White Blood Cell Count and the Risk of Colon Cancer이혜리, 지선하, 남정모, 황유경, 이용제pp. 646-656Soft Tissue Surgery for Equinus Deformity in Spastic Hemiplegic Cerebral Palsy: Effects on Kinematic and Kinetic Parameters박은숙, 김현우, 나동욱, 박창일pp. 657-666
원문 보기